The job cuts reflect the normal maturation of companies such as Alameda-based Scribe, which is moving from a preclinical to ...

WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing ...

Merck just closed a deal to develop a weight-loss drug. The market appears to think Viking Therapeutics is threatened by that data. There's little reason to write off Viking here. First ...

A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D., mere days after she and the company were named in a proposed class ...

Summit Therapeutics' leading candidate is a highly promising cancer medicine. This drug performed better than the market leader in an important indication. Summit Therapeutics should make ...

STAMFORD, Conn. and HOUSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) and Tvardi Therapeutics, Inc. (“Tvardi”), a privately held ...

Keros Therapeutics paused 3.0 mg/kg and 4.5 mg/kg dosing in the TROPOS trial due to adverse pericardial effusion events. Dosing at 1.5 mg/kg continues; topline data for all arms expected in Q2 2025.

Dec 12 (Reuters) - Keros Therapeutics (KROS.O), opens new tab said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of ...

Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million ...

Chroma Medicine and Nvelop Therapeutics merge to bring together best-in-class epigenetic editing technologies and next generation in vivo delivery technologies to unlock the full potential of ...

POTOMAC, Md.--(BUSINESS WIRE)--Versant Ventures today announced the debut of Pep2Tango Therapeutics Inc., a startup focused on innovative, next-generation weight loss therapies. Proceeds from the ...